United Kingdom Osteoporosis Treatment Market By Drug Class (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others), By Route of Administration (Oral, Parental, and Others), By Application (Primary Osteoporosis, Secondary Osteoporosis), By Region, Competition, Forecast & Opportunities, 2028F

United Kingdom osteoporosis market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing demand for diagnostic tests because it gives some benefits such as early detection and diagnosis, accurate diagnosis, tailored treatment plans and monitoring treatment efficacy along with growing demand for medications intake as daily routine for bone benefits. Also, increasing demand for bisphosphonates and hormone replacement therapy (HRT) additives along with growing demand for lifestyle modifications and fracture prevention strategies such as calcium and vitamin D intake, regular weight-bearing exercises, smoking cessation, alcohol moderation and fall prevention measures, home safety assessments, and assistive devices is expected to create a lucrative growth of United Kingdom osteoporosis market during the forecast period.

One in five female fractured patients break three or more bones before getting help. In UK, over 3 million are estimated to have osteoporosis, and over 500,000 fragility fractures are estimated to happen each year.

Increase In Osteoporosis-Related Fractures Drives the Market

Approximately 2.4% of UK healthcare spending, or USD 5.5 billion out of USD 227.2 billion in 2019, was spent on osteoporotic fractures.

The increase in osteoporosis-related fractures stimulates research and innovation in the field of osteoporosis treatment. Pharmaceutical companies and researchers invest in developing new medications, therapies, and technologies to address the rising demand. It leads to advancements in treatment options and drives the United Kingdom osteoporosis treatment market.

Increase in Sedentary Lifestyle

Over 80% of office goers in the UK spend between four to nine hours per day at their desks, which equates to 67 sedentary days on an average. Annually around 1/3 (34%) of men and ½ (42%) of women are not active enough for good health.

The recognition of the detrimental effects of sedentary lifestyles on bone health and the increased risk of osteoporosis can lead to greater awareness among both healthcare professionals and the general population. This awareness can drive the demand for osteoporosis screening and diagnosis, as individuals become more proactive in assessing their bone health and seeking appropriate treatment. The rise in sedentary lifestyles prompts the development of lifestyle modification programs aimed at promoting physical activity and reducing sedentary behavior. These programs may include exercise regimens specifically designed to improve bone health, promote muscle strength and balance, and reduce the risk of falls and fractures. The demand for such programs contributes to the growth of the United Kingdom osteoporosis treatment market.

Aging Population Adds to the Growth of Market

Age is a significant fracture risk factor. According to estimates, the number of people in the UK who are 50 or older will rise by 13.2% between 2019 and 2034. Further increases may be seen amongst men and women who are 75 years or older42.2% for men and 31.0% for women. As a result, fragility fractures are expected to become more common and cause more harm.

1 out of 2 women and up to 1 out of 4 men over age 50.

Recent Development

In 2017, UCL and Amgen announced a collaboration focused on the discovery and development of new therapeutic targets for musculoskeletal diseases, including osteoporosis. The collaboration aimed to leverage UCL's expertise in musculoskeletal biology and Amgen's capabilities in drug discovery to identify potential novel therapies.

In 2011, Novartis acquired Alcon, a multinational eye care company. While Alcon's focus is primarily on eye care, the acquisition expanded Novartis' presence in the healthcare market, potentially influence their offerings in areas such as osteoporosis treatment.

In 2019, the University of Liverpool and Eli Lilly announced a collaboration to investigate the effects of osteoporosis treatments on cardiovascular health. The partnership aimed to improve the understanding of the cardiovascular risks associated with osteoporosis medications and identify potential strategies to optimize treatment outcomes.

Market Segmentation

The United Kingdom osteoporosis treatment market can be segmented by drug class, route of administration, application, and region. Based on drug class, the market can be segmented into parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others. Based on route of administration, the market can be segmented into oral, parenteral, and others. Based on application, the market can be bifurcated into primary osteoporosis and secondary osteoporosis. Based on region, the market can be grouped into Scotland, South- East, London, South-West, Yorkshire & Humberside, East Midlands

Market Players

GlaxoSmithKline Ltd, AstraZeneca Ltd, Amgen Ltd, Eli Lilly & Co, Pfizer Ltd, Novartis Ltd, Merck & Co., UCB Pharma Ltd, Johnson & Johnson Ltd, Servier Pharmaceuticals LLC/United Kingdom are some of the leading players operating in the United Kingdom osteoporosis treatment market.